Reversing Resistance to Counter Antimicrobial Resistance in the World Health Organisation's Critical Priority of Most Dangerous Pathogens

Overview

Journal Biosci Rep

Specialty Cell Biology

Date 2019 Mar 27

PMID 30910848

Citations 29

Authors

Henrietta Venter

Affiliations

Soon will be listed here.

Abstract

The speed at which bacteria develop antimicrobial resistance far outpace drug discovery and development efforts resulting in untreatable infections. The World Health Organisation recently released a list of pathogens in urgent need for the development of new antimicrobials. The organisms that are listed as the most critical priority are all Gram-negative bacteria resistant to the carbapenem class of antibiotics. Carbapenem resistance in these organisms is typified by intrinsic resistance due to the expression of antibiotic efflux pumps and the permeability barrier presented by the outer membrane, as well as by acquired resistance due to the acquisition of enzymes able to degrade β-lactam antibiotics. In this perspective article we argue the case for reversing resistance by targeting these resistance mechanisms - to increase our arsenal of available antibiotics and drastically reduce antibiotic discovery times - as the most effective way to combat antimicrobial resistance in these high priority pathogens.

Citing Articles

Antibiofilm Activities of Tritrpticin Analogs Against Pathogenic PA01 Strains.

Ramamourthy G, Ishida H, Vogel H Molecules. 2025; 30(4).

PMID: 40005137 PMC: 11858513. DOI: 10.3390/molecules30040826.

Harmine acts as a quorum sensing inhibitor decreasing the virulence and antibiotic resistance of Pseudomonas aeruginosa.

Chen P, Qin J, Su H, Du L, Zeng Q BMC Infect Dis. 2024; 24(1):760.

PMID: 39085766 PMC: 11293143. DOI: 10.1186/s12879-024-09639-9.

Investigating the anti-growth, anti-resistance, and anti-virulence activities of J.F.Gmel. against the superbug .

Uc-Cachon A, Dzul-Beh A, Gonzalez-Cortazar M, Zamilpa-Alvarez A, Molina-Salinas G Heliyon. 2024; 10(10):e31420.

PMID: 38813144 PMC: 11133943. DOI: 10.1016/j.heliyon.2024.e31420.

Antibiotic adjuvants: synergistic tool to combat multi-drug resistant pathogens.

Kumar V, Yasmeen N, Pandey A, Chaudhary A, Alawam A, Rudayni H Front Cell Infect Microbiol. 2024; 13:1293633.

PMID: 38179424 PMC: 10765517. DOI: 10.3389/fcimb.2023.1293633.

Chinese herbal compound for multidrug-resistant or extensively drug-resistant bacterial pneumonia: a meta-analysis and trial sequential analysis with association rule mining to identify core herb combinations.

Zhao S, Geng Y, Shi J, Qian J, Yang Y, Dai D Front Pharmacol. 2024; 14:1282538.

PMID: 38174222 PMC: 10761442. DOI: 10.3389/fphar.2023.1282538.

References

Vergalli J, Dumont E, Pajovic J, Cinquin B, Maigre L, Masi M . Spectrofluorimetric quantification of antibiotic drug concentration in bacterial cells for the characterization of translocation across bacterial membranes. Nat Protoc. 2018; 13(6):1348-1361. DOI: 10.1038/nprot.2018.036. View

McCusker M, Alves Ferreira D, Cooney D, Martins Alves B, Fanning S, Pages J . Modulation of antimicrobial resistance in clinical isolates of Enterobacter aerogenes: A strategy combining antibiotics and chemosensitisers. J Glob Antimicrob Resist. 2018; 16:187-198. DOI: 10.1016/j.jgar.2018.10.009. View

Allam A, Maigre L, Vergalli J, Dumont E, Cinquin B, Alves de Sousa R . Microspectrofluorimetry to dissect the permeation of ceftazidime in Gram-negative bacteria. Sci Rep. 2017; 7(1):986. PMC: 5430551. DOI: 10.1038/s41598-017-00945-8. View

Bolla J, Alibert-Franco S, Handzlik J, Chevalier J, Mahamoud A, Boyer G . Strategies for bypassing the membrane barrier in multidrug resistant Gram-negative bacteria. FEBS Lett. 2011; 585(11):1682-90. DOI: 10.1016/j.febslet.2011.04.054. View

Bettiol E, Wetherington J, Schmitt N, Harbarth S . Challenges and solutions for clinical development of new antibacterial agents: results of a survey among pharmaceutical industry professionals. Antimicrob Agents Chemother. 2015; 59(7):3695-9. PMC: 4468719. DOI: 10.1128/AAC.00638-15. View

Wang Y, Venter H, Ma S . Efflux Pump Inhibitors: A Novel Approach to Combat Efflux-Mediated Drug Resistance in Bacteria. Curr Drug Targets. 2015; 17(6):702-19. DOI: 10.2174/1389450116666151001103948. View

Bajaj H, Acosta Gutierrez S, Bodrenko I, Malloci G, Scorciapino M, Winterhalter M . Bacterial Outer Membrane Porins as Electrostatic Nanosieves: Exploring Transport Rules of Small Polar Molecules. ACS Nano. 2017; 11(6):5465-5473. DOI: 10.1021/acsnano.6b08613. View

Citorik R, Mimee M, Lu T . Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat Biotechnol. 2014; 32(11):1141-5. PMC: 4237163. DOI: 10.1038/nbt.3011. View

Vaara M . Agents that increase the permeability of the outer membrane. Microbiol Rev. 1992; 56(3):395-411. PMC: 372877. DOI: 10.1128/mr.56.3.395-411.1992. View

10.

Verchere A, Dezi M, Adrien V, Broutin I, Picard M . In vitro transport activity of the fully assembled MexAB-OprM efflux pump from Pseudomonas aeruginosa. Nat Commun. 2015; 6:6890. DOI: 10.1038/ncomms7890. View

11.

Watkins R, Papp-Wallace K, Drawz S, Bonomo R . Novel β-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistance. Front Microbiol. 2014; 4:392. PMC: 3871716. DOI: 10.3389/fmicb.2013.00392. View

12.

Poole K . Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. J Mol Microbiol Biotechnol. 2001; 3(2):255-64. View

13.

Fernandes P, Martens E . Antibiotics in late clinical development. Biochem Pharmacol. 2016; 133:152-163. DOI: 10.1016/j.bcp.2016.09.025. View

14.

Schumacher A, Trittler R, Bohnert J, Kummerer K, Pages J, Kern W . Intracellular accumulation of linezolid in Escherichia coli, Citrobacter freundii and Enterobacter aerogenes: role of enhanced efflux pump activity and inactivation. J Antimicrob Chemother. 2006; 59(6):1261-4. DOI: 10.1093/jac/dkl380. View

15.

Cheng Y, Lin T, Lin Y, Wang J . A putative RND-type efflux pump, H239_3064, contributes to colistin resistance through CrrB in Klebsiella pneumoniae. J Antimicrob Chemother. 2018; 73(6):1509-1516. PMC: 5961088. DOI: 10.1093/jac/dky054. View

16.

Hackel M, Lomovskaya O, Dudley M, Karlowsky J, Sahm D . Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae. Antimicrob Agents Chemother. 2017; 62(1). PMC: 5740317. DOI: 10.1128/AAC.01904-17. View

17.

Ruggerone P, Murakami S, Pos K, Vargiu A . RND efflux pumps: structural information translated into function and inhibition mechanisms. Curr Top Med Chem. 2013; 13(24):3079-100. DOI: 10.2174/15680266113136660220. View

18.

Daury L, Orange F, Taveau J, Verchere A, Monlezun L, Gounou C . Tripartite assembly of RND multidrug efflux pumps. Nat Commun. 2016; 7:10731. PMC: 4754349. DOI: 10.1038/ncomms10731. View

19.

Ricci V, Tzakas P, Buckley A, Piddock L . Ciprofloxacin-resistant Salmonella enterica serovar Typhimurium strains are difficult to select in the absence of AcrB and TolC. Antimicrob Agents Chemother. 2005; 50(1):38-42. PMC: 1346778. DOI: 10.1128/AAC.50.1.38-42.2006. View

20.

Daly S, Sturge C, Felder-Scott C, Geller B, Greenberg D . MCR-1 Inhibition with Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers Restores Sensitivity to Polymyxin in . mBio. 2017; 8(6). PMC: 5676038. DOI: 10.1128/mBio.01315-17. View